미국 · 보도자료 · SMMT · 2026-10-05 11:00
아스트라제네카, 서밋 테라퓨틱스에 20억 달러 지분 투자 완료
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purch
